EISAI CO LTD

Japan’s Eisai secures China NMPA approval for Bioarctic subcutaneous auto‑therapy, boosting its foothold in the 7 % CAGR autoimmune uveitis market.

New at‑home LEQEMBI® subcutaneous autoinjector cleared by the FDA, matching IV efficacy and opening early‑stage Alzheimer’s treatment to patients worldwide.

Projected Leqembi sales hit ¥300 billion in FY 2029, showing strong growth for Eisai’s Alzheimer’s therapy and boosting its market value.

Projected Leqembi® revenue for FY 2026 hits ¥143.5 billion—Eisai’s strongest Alzheimer’s drug growth, driven by a 63 % jump and BioArctic royalty partnership.

Read how Eisai’s subcutaneous Leqembi gained Chinese regulatory acceptance, unlocking a new Alzheimer’s market and boosting its portfolio.

Eisai Co., Ltd. is preparing to release its financial report, with analysts projecting a decline in earnings per share, but the company is also expecting robust revenue from its Alzheimer’s treatment, Leqembi.